Skip to main content
Caplight Logo









ViroVet

ViroVet

Private
LeuvenHealthcare & Life Scienceshttps://www.virovet.com/

Last Round

Series C

Jun 16, 2022

Total Funding Raised

$24.05M

Company Overview

ViroVet is a biotechnology company that develops innovative technologies, including antiviral drugs and vaccines, for the control of viral diseases in livestock.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

animal healthveterinary biotechnologylivestock vaccinesantiviral drugsanimal pharmaveterinary medicinevaccine developmentsmall molecule therapeuticsepizootic disease controlbiotech licensingpreclinical researchanimal health techagritech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ViroVet Comparables

Compare ViroVet with similar companies based on industry and business-model similarity.

ViroVet comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VEROVACCiNES GmbH
81%
The Vaccine Group
80%
Genvax Technologies
78%

ViroVet Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJun 16, 2022
Series BMay 28, 2020
GrantSep 1, 2018
Series A ExtensionOct 4, 2017
Series AJan 10, 2017

Key People

Founding team and executive leadership

Stefaan Wera

Chief Operating Officer Co-founder

Founding Team

Erwin Blomsma

CEO And Co-founder

Founding Team

ViroVet Investors

Notable investors and investment history

ViroVet investors
InvestorRounds
Capricorn PartnersSeries B, Series C, Series A, Series A Extension
GimvSeries B, Series C
KU Leuven Research & Development (LRD)Series B, Series C
KU LeuvenSeries B, Series A
VIVES II - Louvain Technology FundSeries B, Series A
VLAIOGrant
VIVES PartnersSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 16, 2022

    Raised $8M from Gimv, Capricorn Partners, and others.

  • May 28, 2020

    $7M round led by Seventure Partners

ViroVet Filings

Explore SEC and related filing metadata, where available.

ViroVet filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ViroVet's valuation, stock price, and market status.

Is ViroVet a public or private company?

ViroVet is a private company.

What is the current stock price of ViroVet?

ViroVet is a private company with no public stock price. No recent secondary market data is available.

How much is ViroVet worth (valuation)?

Valuation information for ViroVet is not publicly available.

Can I buy ViroVet stock?

ViroVet shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ViroVet's last funding round?

ViroVet's most recent funding round was Series C on June 16, 2022.

Who are the main investors in ViroVet?

Key investors in ViroVet include Capricorn Partners, PMV, Maatschappij voor Roerend Bezit van de Boerenbond, Seventure Partners.

Will ViroVet IPO soon?

No public IPO plans have been announced for ViroVet.

How can I track ViroVet secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ViroVet's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLeuven
Employee Range9
Year Founded2015
Last FundingJun 16, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?